J-Pharma, a Tokyo Stock Exchange Growth-market drug developer, said on 5 October that its global Phase 3 trial of nanvuranlat (JPH203) in second-line biliary tract cancer, Beacon-BTC, was selected for subsidy support of up to ¥1.5bn from the Japan Agency for Medical Research and Development (AMED).
What the grant covers
The money comes from AMED's fiscal 2026 GRiT programme for rare and intractable disease drug development. J-Pharma applied for ¥1.5bn. The subsidy rate is one-half of eligible costs for the international trial. The planned project period runs from October 2026 to December 2028. The company said the actual amount will be set only after formal grant-decision procedures, and it will now file its grant application.
J-Pharma said 25 projects applied and eight were selected. Its project excluded feasibility studies, the preliminary work on patient numbers and regulator consultations, so it avoids the stage-gate review that feasibility-study projects face after that phase.
Financing runway, with a condition
The company says that if the full ¥1.5bn is paid, combined with existing cash its current development and funding plan can finish Part A without relying on additional fundraising. It describes the grant as non-dilutive, meaning it does not involve issuing shares.
Trial expansion
Part A, which selects the optimal dose and regimen, has already started in the United States, where patient enrolment is under way. J-Pharma plans to run it as an international trial including Japan and will announce a new implementation plan when it can.
The company said it is still assessing the effect on its development budget and earnings forecast. The release does not say when a grant decision is due. Selection does not show that the trial will succeed or that the drug will win approval.